Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:00159857 | Breast | Precancer | energy coupled proton transport, down electrochemical gradient | 16/1080 | 26/18723 | 4.15e-14 | 9.65e-12 | 16 |
GO:00159867 | Breast | Precancer | ATP synthesis coupled proton transport | 16/1080 | 26/18723 | 4.15e-14 | 9.65e-12 | 16 |
GO:00427766 | Breast | Precancer | mitochondrial ATP synthesis coupled proton transport | 13/1080 | 19/18723 | 1.43e-12 | 2.74e-10 | 13 |
GO:00067547 | Breast | Precancer | ATP biosynthetic process | 21/1080 | 57/18723 | 2.31e-12 | 4.26e-10 | 21 |
GO:00068398 | Breast | Precancer | mitochondrial transport | 45/1080 | 254/18723 | 1.37e-11 | 1.88e-09 | 45 |
GO:00092067 | Breast | Precancer | purine ribonucleoside triphosphate biosynthetic process | 22/1080 | 68/18723 | 1.41e-11 | 1.88e-09 | 22 |
GO:00091457 | Breast | Precancer | purine nucleoside triphosphate biosynthetic process | 22/1080 | 69/18723 | 1.95e-11 | 2.43e-09 | 22 |
GO:00092017 | Breast | Precancer | ribonucleoside triphosphate biosynthetic process | 22/1080 | 74/18723 | 9.18e-11 | 1.00e-08 | 22 |
GO:00091448 | Breast | Precancer | purine nucleoside triphosphate metabolic process | 24/1080 | 88/18723 | 9.66e-11 | 1.03e-08 | 24 |
GO:00092057 | Breast | Precancer | purine ribonucleoside triphosphate metabolic process | 23/1080 | 82/18723 | 1.27e-10 | 1.34e-08 | 23 |
GO:00091427 | Breast | Precancer | nucleoside triphosphate biosynthetic process | 23/1080 | 85/18723 | 2.82e-10 | 2.69e-08 | 23 |
GO:00091997 | Breast | Precancer | ribonucleoside triphosphate metabolic process | 23/1080 | 89/18723 | 7.65e-10 | 6.66e-08 | 23 |
GO:00091418 | Breast | Precancer | nucleoside triphosphate metabolic process | 26/1080 | 112/18723 | 7.72e-10 | 6.66e-08 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5F1 | SNV | Missense_Mutation | | c.155N>T | p.Gly52Val | p.G52V | P24539 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.482N>G | p.Gln161Arg | p.Q161R | P24539 | protein_coding | deleterious(0) | benign(0.184) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ATP5F1 | insertion | Frame_Shift_Ins | novel | c.116_117insCCTGATGACAAAGAACAGTACCTGTGTGGGGAGA | p.His40LeufsTer21 | p.H40Lfs*21 | P24539 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ATP5F1 | SNV | Missense_Mutation | novel | c.109G>T | p.Gly37Trp | p.G37W | P24539 | protein_coding | deleterious(0.01) | possibly_damaging(0.604) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | | c.373N>A | p.Asp125Asn | p.D125N | P24539 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | | c.618G>A | p.Met206Ile | p.M206I | P24539 | protein_coding | tolerated(0.41) | benign(0.049) | TCGA-DS-A0VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | novel | c.385N>A | p.Glu129Lys | p.E129K | P24539 | protein_coding | deleterious(0.01) | benign(0.171) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
ATP5F1 | SNV | Missense_Mutation | rs770948319 | c.406G>A | p.Glu136Lys | p.E136K | P24539 | protein_coding | tolerated(0.52) | possibly_damaging(0.564) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.582G>T | p.Lys194Asn | p.K194N | P24539 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP5F1 | SNV | Missense_Mutation | | c.189N>A | p.Phe63Leu | p.F63L | P24539 | protein_coding | tolerated(0.24) | benign(0.027) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |